All In Biotech

Drug Trial Radar · NCT04752540

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

Last checked: Nov 19, 2026Latest source record: Mar 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jul 2, 2021

Primary completion

Oct 24, 2021

Study completion Oct 24, 2021

Sponsor

Lead sponsor
F2G Biotech GmbHIndustry
Sponsor type
Industry
First posted
Feb 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single oral dose study to investigate the PK and safety of olorofim in mild and moderately hepatically impaired subjects compared to subjects with normal hepatic function.

Conditions

  • Hepatic Impairment

Interventions

  • OlorofimDrug

    single oral dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to the time of the last quantifiable concentration (AUC 0-t)Time frame: 0-96 hours
  2. Maximum Observed Plasma Concentration (Cmax)Time frame: 0-96 hours

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Orange County Research Centre

    Tustin, California

  • Orlando Clinical Research Centre

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.